Journal of the American Heart Association

Urinary cadmium linked to higher immune marker levels

An increase in urinary cadmium spanning the middle half of measured levels was associated with 7.99% higher levels of an immune-activation marker.

Paper by Bahjat Z. Ghazzal, Anis Ismail, Theresa Farhat, +10 more authorsSalim S. Hayek · University of Massachusetts Chan Medical School · University of Michigan
Blood cells amid sparse and dense immune markers sit beside groups of people and urine droplets containing fewer or more metal flecks.

Our read

Populations
Studied:
Cohort study of 5,148 adults free of clinical CVD, median 14.7 years
What changed:
suPAR was 7.99% higher per interquartile-range increase in urinary cadmium
The catch:
Participants had no clinical cardiovascular disease, limiting applicability to people with existing disease
In the record:
The 117th paper on cadmium with results in people; 232 on record in all. Its result on mortality agrees with all 6 other findings on record.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

An observational study followed 5,148 adults without clinical cardiovascular disease at enrollment in 2000–2002. Researchers analyzed 11 urinary metals and soluble urokinase plasminogen activator receptor (suPAR), a blood marker of immune activation.

Seven metals were associated with suPAR. Cadmium had the strongest association, which persisted among people who had never smoked. It was more strongly associated with suPAR than with three other markers. Over a median 14.7 years, participants in the highest quarter of urinary cadmium had a higher risk of death from any cause than those in the lowest quarter (hazard ratio 1.43, a relative measure of risk). An exploratory analysis identified a component of the cadmium–death association linked to suPAR. Findings for cardiovascular outcomes pointed in the same direction but were not definitive.

Why it matters

Immune activation offers a possible focus for investigating how environmental metal exposure relates to mortality and lifespan.

Caveats

This observational study cannot establish that cadmium caused immune activation or death; the proposed pathway needs longitudinal and mechanistic confirmation. The participants initially had no clinical cardiovascular disease, limiting applicability to people with existing disease.

Where the evidence stands

Cadmium

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 81 independent labs in 17 countries
  • 9 findings against
  • Funders: National Natural Science Foundation of China and others
  • 2 of 187 findings with company ties

Barium

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 9 independent labs in 2 countries
  • 2 trials
  • Funders: National Natural Science Foundation of China and others

Comments

Be the first to comment.